IOM Panel Backs Public Disclosure Of Drug Company Payments

See allHide authors and affiliations

Science  01 May 2009:
Vol. 324, Issue 5927, pp. 579
DOI: 10.1126/science.324_579a

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


The best way to damp down concerns about doctors' and researchers' financial conflicts of interest is to require full disclosure, according to an expert report that adds its voice to a growing chorus. A panel of the National Academies' Institute of Medicine (IOM) says faculty members at medical institutions should be required to report all industry money they receive from outside their institution--no matter how small the amount--to special committees that would keep track of the data and manage conflicts. Such payments would also have to be reported publicly by the companies.